(FMI)—Given the minuscule deal price, I would say the CGIX purchase of Gentris can’t be highly consequential from a competitive standpoint. What do you think?
I couldn't find any info on what they'd ACTUALLY DONE; or what SPECIFIC technology or capability they actually have. Before the CGIX purchase, I'd never heard of them before.
I would tend to give less value to a company with lofty objectives but no documented achievements. However that would still be an uninformed conclusion. That's why I was seeking insights here.
Their words are nice, but they're totally devoid of any reference to an actual collaboration or achievement. an example from their website:
Gentris has extensive expertise in implementing pharmacogenomics and biorepositories for clinical trials. Our team has implemented GLP and CLIA studies for biotech and pharma companies and has been involved in writing voluntary genomic data submissions and clinical protocols. Clients can benefit from 10 years of experience at the cutting edge of PGx testing by working with Gentris experts to plan new studies, troubleshoot assays or study designs, interpret data, etc. Clients frequently ask for guidance in the following areas:
Pharmacogenomics Implementation Clinical Trial Design Informed Consent Assay Development Assay Development Technologies for Pharmacogenomics GLP/GCP/CLIA/ISBER regulations
Quality Systems Regulatory Compliance Sample Shipment Sample Logistics Sample Handling and Storage
Advantage of Using Gentris’ Consulting Capabilities
Expertise in developing validated pharmacogenomic assays to support all phases of clinical trials Extensive experience with regulatory agencies in the U.S., E.U., and Japan Seamless integration with CRO partners Recognized thought leaders with extensive domain expertise Recognized thought leaders with extensive domain expertise Solid history of successful engagements with top pharma and biotech companies
Market Data 
Markets 
AI
